Endocrine & Diabetes
Beximco Pharma offers wide range of products ensuring effective treatment of type II diabetes. It has the generic versions of all the leading research molecules including Glipizide, Gliclazide, Metformin, Glimepiride, Pioglitazone, Repaglinide etc.
CoDiaglit
CoDiaglit 500 & CoDiaglit 850
(Pioglitazone 15mg & Metformin HCl 500mg) and (Pioglitazone 15mg & Metformin HCl 850mg)
CoDiaglit® (Pioglitazone Hydrochloride and Metformin Hydrochloride) combines two antihyperglycemic agents with different mechanisms of action to improve glycemic control in patients with type 2 diabetes: Pioglitazone hydrochloride, a member of the thiazolidinedione class, and Metformin hydrochloride, a member of the biguanide class. CoDiaglit® is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes who are already treated with a combination of Pioglitazone and Metformin as separate tablets or whose diabetes is not adequately controlled with Metformin alone, or for those patients who have initially responded to Pioglitazone alone and require additional glycemic control.
Diactin
( Glipizide Tablet )
Diactin® is an oral blood glucose lowering drug of the sulfonylurea class. Diactin® is used to treat patients with type 2 diabetes mellitus. Type 2 diabetes mellitus is a condition in which the body does not make enough insulin or where the insulin that the body produces does not work as well as it should. Insulin is a natural body chemical that helps the body's cells use the sugar from the blood and so stops the blood sugar levels from rising too high. High blood sugar levels can cause damage to the body's cells. Diactin® lowers the blood glucose by stimulating release of insulin from pancreatic beta cells and by increasing the sensitivity of peripheral tissues to insulin. Diactin® is indicated as an adjunct to diet for the control of hyperglycaemia and its associated symptomatology in the treatment of non-insulin-dependent diabetes mellitus (type II) when diet modification has not been proved effective on its own. In certain patients who are receiving insulin, the concurrent use of Diactin would allow a reduction in the daily dose of insulin.
Diaglit
( Pioglitazone Tablet )
Diaglit® is a member of the newest class of oral antidiabetic agent called thiazolidinediones that depends on the presence of insulin for its mechanism of action. Pdiglitone decreases insulin resistance in the periphery and in the liver, resulting in increased insulin-dependent glucose disposal and decreased hepatic glucose output. It also improves abnormality in lipid metabolism by activating PPARγ (Peroxisome Proliferator Activated Receptor Gamma) receptor. Diaglit® is indicated as an adjunct to diet and exercise to improve glycaemic control in patients with type II diabetes . Diaglit® is indicated for monotherapy and also indicated for use in combination with sulfonylurea, metformin or insulin when diet and exercise plus the single agent does not result in adequate glycaemic control.
Diapro
( Gliclazide Tablet )
Diapro® is an oral blood glucose lowering drug of the sulfonylurea class. Diapro® is used to treat patients with type 2 diabetes mellitus or non-insulin dependent diabetes mellitus. The primary mechanism of action of Diapro® is lowering of blood glucose by stimulating the release of insulin from functioning pancreatic beta cells. In addition, expancreatic effects may also play vital role in the activity of Diapro®. Administration of Diapro® can lead to increase sensitivity of peripheral tissues to insulin. Diapro® is indicated for non-insulin dependent (type-II) diabetes, whenever blood sugar levels cannot be controlled adequately by diet, physical exercise and weight reduction. Diapro® is also indicated for use in combination with insulin to lower blood glucose in patients whose hyperglycaemia can not be controlled by diet and exercise or in conjunction with an oral hypoglycaemic agent.
Diaryl
( Glimepiride Tablet )
Diaryl® is an oral blood glucose lowering drug of the sulfonylurea class.Diaryl® is used to treat patients with type 2 diabetes mellitus. The primary mechanism of action of Diaryl® is lowering of blood glucose by stimulating the release of insulin from functioning pancreatic beta cells. In addition, expancreatic effects may also play vital role in the activity of Diaryl® . Administration of Diaryl® can lead to increase sensitivity of peripheral tissues to insulin. Diaryl® is indicated for non-insulin dependent (type-II) diabetes, whenever blood sugar levels cannot be controlled adequately by diet, physical exercise and weight reduction.Diaryl® is also indicated for use in combination with insulin to lower blood glucose in patients whose hyperglycaemia can not be controlled by diet and exercise or in conjunction with an oral hypoglycaemic agent.
Fertil
( Clomiphene Citrate Tablet )
Fertil® is an ovulatory stimulant which is indicated for the treatment of ovulatory dysfunction in women desiring pregnancy.Clomiphene citrate is indicated for the treatment of ovulatory failure in women desiring pregnancy whose partners are fertile and potent.
Glipita
(Sitagliptin 50 mg & 100 mg tablets)
Sitagliptin is a new oral agent approved by the US FDA to treat Type 2 diabetes. This is the first approved agent in a new class of antihyperglycemics, dipeptidyl peptidase (DPP)-4 inhibitors. Sitagliptin targets insufficient insulin release and hepatic glucose overproduction in a glucose depended manner. Sitagliptin works to competitively inhibit the enzyme dipeptidyl peptidase 4 (DPP-4). The DPP-4 enzyme inactivates incretin hormones, which are involved in the physiologic regulation of glucose homeostasis. By inhibiting DPP-4, Sitagliptin increases and prolongs active incretin levels. This in turn increases insulin release and decreases glucagon levels in the circulation in a glucose-dependent manner. .Sitagliptin indicated in Type 2 Diabetes Mellitus, in persons≥18 years old, who have failed dietary measures and exercise as dual combination therapy with Metformin or with a sulfonylurea, or with a thiazolidinedione where the use of a thiazolidinedione is considered appropriate Offers excellent safety profile as monotherapy
Glipita M
(Sitagliptin/Metformin HCl)
Glipita® M (Sitagliptin/Metformin HCl) tablets contain two oral antihyperglycemic drugs used in the management of type 2 diabetes: Sitagliptin and Metformin HCl.
Glipita-M is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both sitagliptin and metformin is appropriate.
Sitagliptin Phosphate is an orally-active, potent, and highly selective inhibitor of the dipeptidyl peptidase-4 (DPP-4) enzyme for the treatment of type 2 diabetes. The DPP-4 inhibitors are a class of agents that act as incretin enhancers. By inhibiting the DPP-4 enzyme, Sitagliptin increases the levels of two known active incretin hormones, glucagon-like peptide-1 (GLP-1) and glucosedependent insulinotropic polypeptide (GIP).
Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization. Unlike sulfonylureas, metformin does not produce hypoglycemia in either patients with type 2 diabetes or normal subjects.
Informet
( Metformin Hydrochloride Tablet )
Informet® and Informet® LA are used to treat type 2 diabetes. This is also known as non-insulin-dependent diabetes mellitus. People with type 2 diabetes are not able to make enough insulin or respond normally to the insulin their bodies make. When this happens, sugar (glucose) builds up in the blood. This can lead to serious medical problems including kidney damage, amputations, and blindness. Diabetes is also closely linked to heart disease. The main goal of treating diabetes is to lower your blood sugar to a normal level. Informet® and Informet® LA have the same active ingredient metformin. However, Informet® LA works longer in your body. Both of these medicines help control your blood sugar in a number of ways. These include helping your body respond better to the insulin it makes naturally, decreasing the amount of sugar your liver makes, and decreasing the amount of sugar your intestines absorb. Informet® and Informet® LA do not cause your body to make more insulin. Because of this, when taken alone, they rarely cause hypoglycemia (low blood sugar), and usually do not cause weight gain. However, when they are taken with a sulfonylurea or with insulin, hypoglycemia is more likely to occur, as is weight gain.
Premil
( Repaglinide Tablet )
Premil® is an oral blood glucose lowering drug. The active ingredient of Premil® is Repaglinide. Repaglinide belongs to a new class of oral antidiabetic drug called meglitinide which stimulates insulin release from ß-cells of pancreas. Repaglinide is indicated as an adjunct to diet and exercise to lower the blood glucose level in patients with type 2 diabetes mellitus whose hyperglycaemia cannot be controlled satisfactorily by diet and exercise alone. It is also indicated for use in combination with metformin to lower blood glucose in patients whose hyperglycaemia cannot be controlled by exercise, diet, and either Repaglinide or metformin alone. Repaglinide binds to specific receptors in the ß-cell membrane leading to the closure of ATP-dependent K+ channels and the depolarization of ß-cell membrane. This in turn, leads to Ca++ influx, increased intracellular Ca++ and the stimualtion of insulin secretion.
Prosfin
( Finasteride Tablet )
Prosfin® is a preparation of Finasteride which is indicated for the treatment and control of benign prostatic hyperplasia (BPH) to cause regression of the enlarged prostate, to improve urinary flow, and to improve the symptoms associated with BPH. The development of the prostate gland and subsequent BPH is dependent upon conversion of testosterone to dihydrotestosterone (DHT) within the prostate. Prosfin® belongs to a new class of specific inhibitors of 5a-reductase, an intracellular enzyme which metabolizes testosterone into the more potent androgen, DHT. Finasteride has no affinity for the androgen receptor.
Recur
( Finasteride coated Tablet )
Recur® is a preparation of Finasteride, a competitive inhibitor of steroid Type II 5a-reductase, an intracellular enzyme that converts the androgen testosterone into 5a-dihydrotestosterone (DHT). Finasteride is a competitive and specific inhibitor of Type II 5a-reductase, an intracellular enzyme that converts the androgen testosterone into DHT. Finasteride has no affinity for the androgen receptor and has no androgenic or antiandrogenic effects. Inhibition of Type II 5a-reductase blocks the conversion of testosterone to DHT, resulting in significant decreases in serum and tissue DHT concentrations. In men with male pattern hair loss, the balding scalp contains miniaturized hair follicles and increased amounts of DHT compared with hairy scalp. Administration of Finasteride decreases scalp and serum DHT concentrations in these men.Recur® is indicated for the treatment of male pattern hair loss (androgenic alopecia) in male patient only.
Welcome to the registered Health Professionals, to this exclusive Doctors only area. This provides you access to latest medical updates, events, guidelines and information relevant to your practice. If you are not a registered doctor please do not enter this area. 
Life's all about staying healthy and enjoying the good things in life! However, illness is inevitable at all stages of life. In this area learn about the common health problems and how to deal with your and your family's illness.